| Identification | |
| Name: | Sitagliptin phosphate |
| Synonyms: | (2R)-4-Oxo-4-(3-(trifluoromethyl)-5,6-dihydro(1,2,4)triazolo(4,3-a)pyrazin-7(8H)-yl)-1-(2,4,5-trifluorophenyl)butan-2-amine phosphate salt;MK 0431; |
| CAS: | 654671-78-0 |
| Molecular Formula: | C16H18F6N5O5P |
| Molecular Weight: | 505.3102 |
| InChI: | InChI=1/C16H15F6N5O.H3O4P/c17-10-6-12(19)11(18)4-8(10)3-9(23)5-14(28)26-1-2-27-13(7-26)24-25-15(27)16(20,21)22;1-5(2,3)4/h4,6,9H,1-3,5,7,23H2;(H3,1,2,3,4)/t9-;/m1./s1 |
| Molecular Structure: |  |
| Properties | |
| Appearance: | white solid |
| Specification: |
?Sitagliptin phosphate (CAS NO.654671-78-0) is also named as 4-Oxo-4-(3-(trifluoromethyl)-5,6-dihydro(1,2,4)triazolo(4,3-a)pyrazin-7(8H)-yl)-1-(2,4,5-trifluorophenyl)butan-2-amine phosphate ; Januvia ; MK 0431 ; MK-0431 ; MK0431?.?Sitagliptin phosphate (CAS NO.654671-78-0) is white solid. |
| Usage: | A trizolopyrazine dipeptidyl peptidase IV inhibitor. It has recently been approved for the therapy of type II diabetes. |
| Safety Data | |
 |
|
